Nuvilex (NASDAQ:PMCB) Shares Down 1.5% – What’s Next?

Nuvilex Inc. (NASDAQ:PMCB)’s stock price traded down 1.5% during trading on Monday . The company traded as low as $0.61 and last traded at $0.6233. Approximately 77,081 shares traded hands during mid-day trading, a decline of 3% from the average session volume of 79,411 shares. The stock had previously closed at $0.6330.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (d)” rating on shares of Nuvilex in a research report on Tuesday, April 21st. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, Nuvilex currently has a consensus rating of “Sell”.

Nuvilex Stock Down 1.5%

The business has a fifty day simple moving average of $0.75 and a 200 day simple moving average of $0.75. The company has a market cap of $6.69 million, a price-to-earnings ratio of -0.56 and a beta of 0.53.

Nuvilex Company Profile

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte.